PainReform (PainReform) Asset Impairment Charge : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PainReform Asset Impairment Charge?

PainReform's Asset Impairment Charge for the three months ended in Mar. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

PainReform Asset Impairment Charge Historical Data

The historical data trend for PainReform's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform Asset Impairment Charge Chart

PainReform Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

PainReform Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

PainReform Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PainReform Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of PainReform's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

PainReform (PainReform) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Yigal Alon Street, Tel Aviv, ISR, 6744316

Website

https://www.painreform.com

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.